🔗 Share this article

The recently developed medications for gonorrhoea in many years are being described as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to health experts.

An International Challenge

Cases of gonorrhoea are increasing globally, with figures suggesting in excess of 82 million instances per year. Particularly high rates are seen in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune development in the reality of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs at this time.”

Medical experts are deeply concerned about the rise in treatment-resistant strains. The WHO has listed it as a "high-priority threat". A tracking program revealed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Secure Authorization

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to significant complications, including infertility. Experts hope that targeted use of this new drug will help hinder the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, gained clearance in the same week. This treatment, which is also used to treat urinary tract infections, was demonstrated in studies to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment was the result of a innovative non-profit model for medication research. The charitable organization GARDP partnered with the pharmaceutical company its industry partner to see it through.

“This authorization represents a significant shift in the treatment of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Results and Global Access

As per data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which combines a dual-drug approach. The study enrolled over 900 patients from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the rights to register and commercialise the drug in many developing nations.

Medical professionals on the front lines have shared positive views. Having a one-pill regimen such as this is described as a "game-changer" for gonorrhoea control. This is deemed vital to alleviate the strain of the disease for individuals and to prevent the spread of untreatable gonorrhoea globally.